top of page
Cerca

DIAGEN UPDATES ON DIABETES - June 2024

  • Immagine del redattore: DiaGen
    DiaGen
  • 4 giu 2024
  • Tempo di lettura: 2 min

Aggiornamento: 14 nov 2024

Body weight loss and control of blood glucose by activation of Glucagon Like Peptide 1 (GLP1) receptor






#newsletter 2: UPDATES ON DIABETES


Body weight loss and control of blood glucose by activation of Glucagon Like Peptide 1 (GLP1) receptor

Activation of GLP1 receptor by semaglutide (commercially sold with the drug name of Ozempic, Wegovy or Rybelsus) has important beneficial effects in obese and/or type II diabetic people; it may reduce body weight and promote a better control of blood glucose. Tirzepatide (commercially sold with the drug name of Mounjaro) is another agonist of GLP1 receptor that also activates Glucose-dependent Insulinotropic Polypeptide (GIP) receptor. Tirzepatide may reduce body weight and improves blood glucose control in type II diabetic patients.


Improvement of cardiovascular and kidney outcomes

Obesity is a risk factor for development of diabetes and its complications, such as cardiovascular diseases and chronic kidney disease (CKD). Prevention of these complications is an important step to improve clinical management of obesity and diabetes. In addition to blood glucose control, it has been reported that GLP1 receptor agonist has also beneficial effects on cardiovascular and kidney physiology in obese non-diabetic and obese diabetic patients. The use of this GLP-1 agonist to improve cardiovascular and kidney outcomes remains to be further studied.


To diminish the loss of lean mass

GLP-1 receptor agonists have a significant effect on body weight loss in overweight people and there is a significant reduction of white adipose tissue but also lean body mass (muscle). This is an undesired side effect and there is a growing effort from pharmaceutical companies to find means to address the loss of lean body mass during the use of GLP-1 receptor agonists. A recent report shows that blockade of activin II receptor prevents the loss of lean mass in overweight patients undergoing GLP-1 agonist treatment. This study also remains to be further confirmed.


Once a week insulin administration

A long-acting insulin analog is produced and designed for a single weekly injection. The use of this insulin analog has an important aspect on the daily routine of diabetic patients given the fact that it reduces the need of insulin injections from 365 days to 52 days a year. In Europe, this drug (commercially known as Awiqli) is approved for use in adults suffering of diabetes mellitus. In the United States, the approval by the Food and Drug Administration (FDA) to use this analog in diabetic patients is still pending due to concerns over its higher risks of hypoglycemia.


DiaGen is a non-profit association that supports groundbreaking projects in the field of diabetes, with potential of making life of diabetic patients better. You can help us to make a difference by donating to Diagen association. Go to our website



To receive our newsletters, contact us.

Thank you for reading our newsletter.




 
 
 

コメント

bottom of page